ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-895-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.82 million
Profitability
Miscellaneous
Employees293
OptionableOptionable
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Friday, February, 8th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.06. The biotechnology company earned $13.79 million during the quarter, compared to analyst estimates of $12.42 million. ImmunoGen had a negative return on equity of 499.19% and a negative net margin of 311.94%. The firm's revenue was down 65.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.11) earnings per share. View ImmunoGen's Earnings History.
When is ImmunoGen's next earnings date?
What guidance has ImmunoGen issued on next quarter's earnings?
ImmunoGen issued an update on its FY 2019 earnings guidance on Friday, February, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $40-45 million, compared to the consensus revenue estimate of $64.43 million.
What price target have analysts set for IMGN?
9 equities research analysts have issued 1-year target prices for ImmunoGen's shares. Their predictions range from $5.00 to $20.00. On average, they expect ImmunoGen's share price to reach $14.60 in the next year. This suggests a possible upside of 158.4% from the stock's current price. View Analyst Price Targets for ImmunoGen.
What is the consensus analysts' recommendation for ImmunoGen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmunoGen.
What are Wall Street analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $18 price target on shares of ImmunoGen is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF analysis is based on: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 12.0%, and tax rate of 12% beginning in FY 2028. Note, our $18 price target is leveraged on the outcome of the mirvetuximab soravtansine’s Phase 3 FORWARD I study, which represents approximately 89% of our target (risk-adjusted NPV of $16 per share). Key risks to our valuation include: emergence of ADC-related safety concerns, clinical, regulatory, and financials risks. ImmunoGen, Inc." (1/3/2019)
- 2. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the industry so far this year." (9/24/2018)
Has ImmunoGen been receiving favorable news coverage?
News coverage about IMGN stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ImmunoGen earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Are investors shorting ImmunoGen?
ImmunoGen saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 14,513,485 shares, a decrease of 10.7% from the January 15th total of 16,243,883 shares. Based on an average daily trading volume, of 2,187,592 shares, the days-to-cover ratio is presently 6.6 days. Currently, 9.9% of the shares of the company are short sold. View ImmunoGen's Current Options Chain.
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA), Endo International (ENDP), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD) and Heron Therapeutics (HRTX).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
- Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
- Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
- Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
- Mr. David Foster, VP of Fin. & Chief Accounting Officer
Who are ImmunoGen's major shareholders?
ImmunoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.30%), Northern Trust Corp (1.19%), Geode Capital Management LLC (1.15%), Two Sigma Investments LP (0.74%), Jennison Associates LLC (0.72%) and Candriam Luxembourg S.C.A. (0.68%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
Which institutional investors are selling ImmunoGen stock?
IMGN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Raymond James & Associates, MetLife Investment Advisors LLC, Pinnacle Associates Ltd., Bank of America Corp DE, Northern Trust Corp, Bank of New York Mellon Corp and Janney Montgomery Scott LLC. Company insiders that have sold ImmunoGen company stock in the last year include Anna Berkenblit, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
Which institutional investors are buying ImmunoGen stock?
IMGN stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Opaleye Management Inc., BlackRock Inc., California Public Employees Retirement System, Squarepoint Ops LLC, Sectoral Asset Management Inc, Two Sigma Advisers LP and Geode Capital Management LLC. View Insider Buying and Selling for ImmunoGen.
How do I buy shares of ImmunoGen?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of IMGN stock can currently be purchased for approximately $5.65.
How big of a company is ImmunoGen?
ImmunoGen has a market capitalization of $842.36 million and generates $53.82 million in revenue each year. The biotechnology company earns $-167,870,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.
What is ImmunoGen's official website?
How can I contact ImmunoGen?
ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
